Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2022 Filed Mar 3, 2022 00:33 UTC |
Calamari Christopher J.SENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 2,368 | $122.41 | $289,866.88 |
DisclosureSEC source: 0001415889-22-002187 · form4-03022022_040347.xml · nonDerivative · entry 1 Calamari Christopher J. · CIK 0001868518 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,364 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:35 UTC |
CAPEK JOHN MEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 7,086 | $122.41 | $867,397.26 |
DisclosureSEC source: 0001415889-22-002188 · form4-03022022_040351.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,835 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:36 UTC |
DALE MICHAEL DSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,505 | $122.41 | $551,457.05 |
DisclosureSEC source: 0001415889-22-002189 · form4-03022022_040327.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,833 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:38 UTC |
Earnhardt Lisa DEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 5,168 | $122.41 | $632,614.88 |
DisclosureSEC source: 0001415889-22-002190 · form4-03022022_040309.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,573 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:40 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
Tax withholdingCommon shares without par value | 26,579 | $122.41 | $3,253,535.39 |
DisclosureSEC source: 0001415889-22-002191 · form4-03022022_040335.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,485 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:44 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 10,750 | $122.41 | $1,315,907.50 |
DisclosureSEC source: 0001415889-22-002192 · form4-03022022_040325.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,582 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:47 UTC |
Ginascol John FEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 5,876 | $122.41 | $719,281.16 |
DisclosureSEC source: 0001415889-22-002193 · form4-03022022_040330.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,045 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:49 UTC |
Karam SammySENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 802 | $122.41 | $98,172.82 |
DisclosureSEC source: 0001415889-22-002194 · form4-03022022_040352.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,662 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:49 UTC |
Karam SammySENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 13,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002194 · form4-03022022_040352.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,464 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:51 UTC |
MANNING JOSEPH JEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 5,850 | $122.41 | $716,098.50 |
DisclosureSEC source: 0001415889-22-002196 · form4-03022022_040308.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,652 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:52 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,112 | $122.41 | $503,349.92 |
DisclosureSEC source: 0001415889-22-002197 · form4-03022022_040347.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,853 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:54 UTC |
Morrone Louis H.SENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 1,942 | $122.41 | $237,720.22 |
DisclosureSEC source: 0001415889-22-002198 · form4-03022022_040330.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,934 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:56 UTC |
PEDERSON MICHAEL JSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,628 | $122.41 | $566,513.48 |
DisclosureSEC source: 0001415889-22-002199 · form4-03022022_040307.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,678 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:58 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 10,551 | $122.41 | $1,291,547.91 |
DisclosureSEC source: 0001415889-22-002200 · form4-03022022_040330.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,798 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:00 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 6,126 | $122.41 | $749,883.66 |
DisclosureSEC source: 0001415889-22-002201 · form4-03022022_050341.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,628 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:02 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 6,759 | $122.41 | $827,369.19 |
DisclosureSEC source: 0001415889-22-002203 · form4-03022022_050343.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,583 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:05 UTC |
Wellisch Alejandro DSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,186 | $122.41 | $512,408.26 |
DisclosureSEC source: 0001415889-22-002204 · form4-03022022_050355.xml · nonDerivative · entry 2 Wellisch Alejandro D · CIK 0001717526 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,832 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:05 UTC |
Wellisch Alejandro DSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 11,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002204 · form4-03022022_050355.xml · nonDerivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,018 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:07 UTC |
WOODGRIFT RANDEL WILLIAMSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,038 | $122.41 | $494,291.58 |
DisclosureSEC source: 0001415889-22-002206 · form4-03022022_050349.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,187 Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:23 UTC |
McKinstry NancyDirector
|
Exercise / conversionOption (right to buy) · Derivative | 6,280 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0001415889-22-001883 · form4-02252022_020241.xml · derivative · entry 3 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,280 shares Expires 2022-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:23 UTC |
McKinstry NancyDirector
|
SaleCommon shares without par value | 1,614 | $116.43 | $187,909.95 |
DisclosureSEC source: 0001415889-22-001883 · form4-02252022_020241.xml · nonDerivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,805 Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:23 UTC |
McKinstry NancyDirector
|
Exercise / conversionCommon shares without par value | 6,280 | $29.84 | $187,393.94 |
DisclosureSEC source: 0001415889-22-001883 · form4-02252022_020241.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 01:00 UTC |
Boudreau Philip PVICE PRESIDENT
|
Tax withholdingCommon shares without par value | 966 | $116.79 | $112,819.14 |
DisclosureSEC source: 0001415889-22-001730 · form4-02232022_050218.xml · nonDerivative · entry 2 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,261 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 01:21 UTC |
Mateus FernandoSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 886 | $116.79 | $103,475.94 |
DisclosureSEC source: 0001415889-22-001741 · form4-02232022_050219.xml · nonDerivative · entry 4 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,960 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 01:23 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 793 | $116.79 | $92,614.47 |
DisclosureSEC source: 0001415889-22-001742 · form4-02232022_050234.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,365 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 01:31 UTC |
Tyler Julie L.SENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 462 | $119.29 | $55,114.01 |
DisclosureSEC source: 0001415889-22-001746 · form4-02232022_050236.xml · nonDerivative · entry 5 Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,703 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.2904 to $119.302, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 01:31 UTC |
Tyler Julie L.SENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 466 | $116.79 | $54,424.14 |
DisclosureSEC source: 0001415889-22-001746 · form4-02232022_050236.xml · nonDerivative · entry 4 Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,165 Read SEC document |
| February 21, 2022 Filed Feb 24, 2022 01:21 UTC |
Mateus FernandoSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 701 | $116.79 | $81,869.79 |
DisclosureSEC source: 0001415889-22-001741 · form4-02232022_050219.xml · nonDerivative · entry 3 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,846 Read SEC document |
| February 21, 2022 Filed Feb 24, 2022 01:31 UTC |
Tyler Julie L.SENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 342 | $116.79 | $39,942.18 |
DisclosureSEC source: 0001415889-22-001746 · form4-02232022_050236.xml · nonDerivative · entry 3 Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,631 Read SEC document |
| February 19, 2022 Filed Feb 24, 2022 01:21 UTC |
Mateus FernandoSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 595 | $116.79 | $69,490.05 |
DisclosureSEC source: 0001415889-22-001741 · form4-02232022_050219.xml · nonDerivative · entry 2 Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,547 Read SEC document |
| February 19, 2022 Filed Feb 24, 2022 01:31 UTC |
Tyler Julie L.SENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 281 | $116.79 | $32,817.99 |
DisclosureSEC source: 0001415889-22-001746 · form4-02232022_050236.xml · nonDerivative · entry 2 Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,973 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 00:56 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 54,280 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001728 · form4-02232022_040210.xml · derivative · entry 3 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,280 Underlying: Common Shares · 54,280 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,093 on February 18, 2023, 18,093 on February 18, 2024, and 18,094 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 00:56 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 11,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001728 · form4-02232022_040210.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,934 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 00:58 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 95,000 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001729 · form4-02232022_040219.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Shares · 95,000 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 31,666 on February 18, 2023, 31,667 on February 18, 2024, and 31,667 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 00:58 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 20,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001729 · form4-02232022_040219.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,423 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:00 UTC |
Boudreau Philip PVICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 24,938 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001730 · form4-02232022_050218.xml · derivative · entry 4 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,938 Underlying: Common Shares · 24,938 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,312 on February 18, 2023, 8,313 on February 18, 2024, and 8,313 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:00 UTC |
Boudreau Philip PVICE PRESIDENT
|
GrantCommon shares without par value | 5,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001730 · form4-02232022_050218.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,227 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:02 UTC |
Calamari Christopher J.SENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 59,708 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001731 · form4-02232022_050208.xml · derivative · entry 4 Calamari Christopher J. · CIK 0001868518 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,708 Underlying: Common Shares · 59,708 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,902 on February 18, 2023, 19,903 on February 18, 2024 and 19,903 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:02 UTC |
Calamari Christopher J.SENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 12,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001731 · form4-02232022_050208.xml · nonDerivative · entry 1 Calamari Christopher J. · CIK 0001868518 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,732 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:04 UTC |
CAPEK JOHN MEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 72,342 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001732 · form4-02232022_050247.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,342 Underlying: Common Shares · 72,342 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,114 on February 18, 2023, 24,114 on February 18, 2024, and 24,114 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:04 UTC |
CAPEK JOHN MEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 15,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001732 · form4-02232022_050247.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,921 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:06 UTC |
DALE MICHAEL DSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 54,280 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001733 · form4-02232022_050253.xml · derivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,280 Underlying: Common Shares · 54,280 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,093 on February 18, 2023, 18,093 on February 18, 2024, and 18,094 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:06 UTC |
DALE MICHAEL DSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 11,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001733 · form4-02232022_050253.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,338 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:07 UTC |
Earnhardt Lisa DEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 80,380 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001734 · form4-02232022_050212.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,380 Underlying: Common Shares · 80,380 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,793 on February 18, 2023, 26,793 on February 18, 2024, and 26,794 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:07 UTC |
Earnhardt Lisa DEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 17,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001734 · form4-02232022_050212.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,741 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:09 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
GrantOption (right to buy) · Derivative | 344,827 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001735 · form4-02232022_050220.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,827 Underlying: Common Shares · 344,827 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 114,942 on February 18, 2023, 114,942 on February 18, 2024, and 114,943 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:09 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
GrantCommon shares without par value | 73,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001735 · form4-02232022_050220.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,064 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:12 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 133,670 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001736 · form4-02232022_050248.xml · derivative · entry 6 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,670 Underlying: Common Shares · 133,670 shares Expires 2032-02-17 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 44,556 on February 18, 2023, 44,557 on February 18, 2024, and 44,557 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:12 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 28,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001736 · form4-02232022_050248.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,332 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:15 UTC |
Ginascol John FEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 80,380 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001738 · form4-02232022_050221.xml · derivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,380 Underlying: Common Shares · 80,380 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,793 on February 18, 2023, 26,793 on February 18, 2024, and 26,794 on February 18, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.